Wall Street analysts forecast that Steris Plc (NYSE:STE) will post $665.47 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Steris’ earnings. The lowest sales estimate is $661.50 million and the highest is $669.90 million. Steris posted sales of $646.77 million during the same quarter last year, which suggests a positive year over year growth rate of 2.9%. The company is expected to issue its next quarterly earnings report on Tuesday, February 6th.

On average, analysts expect that Steris will report full year sales of $665.47 million for the current year, with estimates ranging from $2.60 billion to $2.62 billion. For the next fiscal year, analysts expect that the business will report sales of $2.72 billion per share, with estimates ranging from $2.71 billion to $2.74 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Steris.

Steris (NYSE:STE) last issued its earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the consensus estimate of $0.95 by ($0.01). The firm had revenue of $634.20 million during the quarter, compared to the consensus estimate of $629.02 million. Steris had a return on equity of 11.49% and a net margin of 5.59%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business earned $0.89 earnings per share.

A number of research analysts have issued reports on the company. Raymond James Financial lifted their price objective on Steris from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, August 9th. Zacks Investment Research upgraded Steris from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research note on Monday, October 9th. TD Securities upped their price objective on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Finally, KeyCorp restated a “buy” rating and issued a $91.00 target price on shares of Steris in a report on Tuesday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $79.50.

In other Steris news, Director Richard Martin Steeves sold 156,072 shares of the stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $87.13, for a total transaction of $13,598,553.36. Following the sale, the director now directly owns 9,362 shares in the company, valued at approximately $815,711.06. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total transaction of $321,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 192,722 shares of company stock valued at $16,913,753. 2.55% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC grew its position in Steris by 1,972.4% during the 2nd quarter. Janus Henderson Group PLC now owns 7,679,507 shares of the medical equipment provider’s stock worth $625,880,000 after purchasing an additional 7,308,950 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Steris by 33.4% in the second quarter. BlackRock Inc. now owns 7,032,984 shares of the medical equipment provider’s stock valued at $573,188,000 after purchasing an additional 1,760,879 shares during the period. Vanguard Group Inc. lifted its stake in shares of Steris by 1.6% in the second quarter. Vanguard Group Inc. now owns 6,879,760 shares of the medical equipment provider’s stock valued at $560,700,000 after purchasing an additional 107,644 shares during the period. FMR LLC lifted its stake in shares of Steris by 33.1% in the second quarter. FMR LLC now owns 3,454,533 shares of the medical equipment provider’s stock valued at $281,544,000 after purchasing an additional 859,228 shares during the period. Finally, State Street Corp raised its position in Steris by 53.2% during the second quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock worth $190,392,000 after acquiring an additional 811,622 shares during the last quarter. 89.44% of the stock is currently owned by institutional investors.

Steris (NYSE STE) opened at $89.96 on Friday. The stock has a market capitalization of $7,563.71, a price-to-earnings ratio of 22.92 and a beta of 1.31. Steris has a twelve month low of $64.37 and a twelve month high of $93.39. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.18 and a current ratio of 2.80.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be paid a dividend of $0.31 per share. The ex-dividend date is Tuesday, November 21st. This represents a $1.24 annualized dividend and a yield of 1.38%. Steris’s dividend payout ratio is presently 73.81%.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/steris-plc-ste-expected-to-announce-quarterly-sales-of-665-47-million.html.

Steris Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Get a free copy of the Zacks research report on Steris (STE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Steris (NYSE:STE)

Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.